PROTECT-HER KIT to Improve HPV Self-Sampling Uptake Among Women in Selangor (PROTECTHER KIT)

November 13, 2026 updated by: Fairuz Alia Rafiai, Universiti Teknologi Mara

Development, Validation, and Evaluation of the Protection Motivation Theory-Based HPV Screening Education Kit (PROTECT-HER KIT) on HPV Self-Sampling Uptake Among the KOSPEN Community in Selangor: A Cluster Randomised Controlled Trial

This study aims to evaluate the effectiveness of the Protection Motivation Theory-Based HPV Screening Education Kit (PROTECT-HER KIT) in improving human papillomavirus (HPV) self-sampling uptake among eligible women in KOSPEN communities in Selangor, Malaysia. The study uses a two-arm, parallel cluster randomised controlled trial involving 106 women aged 30-65 years across eight KOSPEN localities. Localities will be randomly allocated to receive either the PROTECT-HER KIT educational intervention or standard Ministry of Health educational materials. The primary outcome is HPV self-sampling uptake assessed at one and two months following the intervention. Secondary outcomes include cervical cancer awareness and protection motivation measured at baseline, one month, and two months.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

The goal of this cluster randomised controlled trial is to evaluate the effectiveness of the Protection Motivation Theory-Based HPV Screening Education Kit (PROTECT-HER KIT) in improving human papillomavirus (HPV) self-sampling uptake, cervical cancer awareness, and protection motivation among eligible women in the Komuniti Sihat Pembina Negara (KOSPEN) communities in Selangor, Malaysia. The PROTECT-HER KIT is a newly developed health education package designed to improve women's knowledge, perceived risk, confidence, and motivation to undergo HPV self-sampling for cervical cancer screening.

The main questions this study aims to answer are:

Will the PROTECT-HER KIT increase HPV self-sampling uptake among eligible women in KOSPEN communities in Selangor?

Will the PROTECT-HER KIT improve cervical cancer awareness among participants?

Will the PROTECT-HER KIT improve protection motivation, including perceived severity, perceived vulnerability, response efficacy, self-efficacy, and perceived response costs related to HPV self-sampling?

To evaluate the effectiveness of the PROTECT-HER KIT, researchers will conduct a two-arm cluster randomised controlled trial involving eight KOSPEN localities in Selangor. The localities will be randomly assigned to either the intervention group or the control group. The intervention group will receive the PROTECT-HER KIT, comprising a structured face-to-face health education session using flipcharts, video demonstrations, facilitated discussions, and practical guidance on HPV self-sampling, followed by WhatsApp reinforcement messages and action-planning reminders. The control group will receive standard cervical cancer prevention educational materials from the Ministry of Health Malaysia.

Participants will:

Complete a baseline questionnaire (T0) assessing their sociodemographic characteristics, cervical cancer awareness, protection motivation, and previous cervical cancer screening history.

Receive either the PROTECT-HER KIT educational intervention or standard Ministry of Health educational materials, depending on the KOSPEN locality to which they belong.

Complete follow-up questionnaires at approximately one month (T1) and two months (T2) after the educational intervention to assess changes in cervical cancer awareness, protection motivation, and HPV self-sampling uptake.

Report whether they have undergone HPV self-sampling for cervical cancer screening during the follow-up period.

The findings will help determine whether a theory-based, community-delivered health education intervention can improve HPV self-sampling uptake and support cervical cancer prevention efforts in Malaysia.

Study Type

Interventional

Enrollment (Estimated)

106

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Putrajaya
      • Petaling Jaya, Putrajaya, Malaysia, 40000
        • Pejabat Kesihatan Daerah Petaling
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  1. Malaysian women aged 30-65 years.
  2. Residing in a participating KOSPEN locality in Selangor.
  3. Able to read and understand Malay.
  4. Never screened or overdue for cervical cancer screening according to current Malaysian guidelines.
  5. Own a smartphone with WhatsApp.

Exclusion Criteria:

  1. Physical or mental impairment preventing participation in study procedures.
  2. Declines to participate or provide informed consent.
  3. Diagnosed cervical cancer or precancerous cervical disease.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PROTECT-HER KIT

Participants will receive a structured, approximately 90-minute face-to-face educational session incorporating four modules: cervical cancer and HPV risk education, HPV self-sampling procedures and skills, emotional and practical barriers, and action planning. Educational materials include flipcharts, video demonstrations, facilitated discussions and standardised WhatsApp reinforcement and reminders.

Participants allocated to the intervention group will receive the PROTECT-HER KIT, a structured educational intervention based on Protection Motivation Theory (PMT) to improve cervical cancer awareness, protection motivation, and HPV self-sampling uptake. The intervention consists of a single approximately 90-minute, face-to-face small-group educational session delivered by the principal researcher using flipcharts, a video demonstration, facilitated discussions, and practical guidance on HPV self-sampling. The educational content addresses perceived severity, perceived vulnerability, response efficacy, self-efficacy, and perceived response costs related to cervical cancer screening. Standardised WhatsApp reinforcement messages and action-planning reminders will be provided following the session to encourage HPV self-sampling uptake. The intervention will be delivered after completion of the baseline assessment (T0).

Active Comparator: Standard Ministry of Health Education

Participants will receive a one-off distribution of existing Ministry of Health educational materials containing general information on women's health and cervical cancer prevention. Participants will continue to have access to routine cervical cancer screening services.

Participants allocated to the control group will receive a one-off distribution of standard health educational materials sourced from the Ministry of Health Malaysia. These materials provide general information on women's health, cervical cancer prevention, and cervical cancer screening. Unlike the intervention group, participants will not receive the structured PROTECT-HER KIT educational session or standardised WhatsApp reinforcement messages. The educational materials will be distributed once following completion of the baseline assessment (T0). Participants will continue to have access to routine cervical cancer screening services.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Secondary: Cervical cancer awareness
Time Frame: Baseline, 1 and 2 months

Cervical Cancer Awareness Scale (Cx-CAS), 15 items

Baseline, 1 and 2 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Secondary: Cervical cancer awareness
Time Frame: Baseline, 1 and 2 months

Cervical Cancer Awareness Scale (Cx-CAS), 15 items

Baseline, 1 and 2 months
Secondary: Protection motivation
Time Frame: Baseline, 1 and 2 months

Adapted Malay PMT questionnaire, 24 items

Baseline, 1 and 2 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 1, 2027

Primary Completion (Estimated)

June 30, 2027

Study Completion (Estimated)

June 30, 2027

Study Registration Dates

First Submitted

November 9, 2026

First Submitted That Met QC Criteria

November 13, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • NMRR ID-26-03000-XRM (IIR)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data (IPD) will not be made publicly available due to the sensitive nature of the information collected, including cervical cancer screening history, HPV self-sampling uptake, and health-related perceptions. Data confidentiality and participant privacy will be maintained in accordance with the approved study protocol, institutional ethical requirements, and applicable data protection regulations. Study findings will be disseminated through scientific publications and presentations in aggregate form without identifying individual participants.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.